On the additional risk of delisting of ordinary shares of bluebird bio, Inc. (BLUE)

The International Trading System Limited (hereinafter — ITS) hereby informs on the additional information concerning delisting risk of ordinary shares of bluebird bio, Inc. (ISIN US09609G1004, hereinafter — Shares, QI) from The Nasdaq Stock Market LLC (hereinafter — Nasdaq).

Information on delisting risk of ordinary shares by Nasdaq

On September 24, 2024 bluebird bio, Inc. (hereinafter – the Company) submitted Current report on Form 8-K to The United States Securities and Exchange Commission (hereinafter – SEC). According to the report, the Company has incurred risks and uncertainties related to the fact that the internal and external costs required for the Company’s ongoing and planned activities, and the resulting impact on expense and use of cash, has been, and may in the future be, higher than expected. These conditions led the Company’s management to raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements. For more information, please refer to the report available on the SEC website.

Information regarding possible actions to be taken by ITS Ltd.

ITS Ltd. conducts regular monitoring of the relevant information disclosed by the Company. Delisting of the Company’s securities (hereinafter – Qualified Investments) by Nasdaq will be considered to constitute a breach of the ITS Regulations on admitting financial instruments to trading and result in termination of trading in the Qualified Investments on ITS.